{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:22:16Z","timestamp":1784694136518,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81302095"],"award-info":[{"award-number":["81302095"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670497"],"award-info":[{"award-number":["81670497"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81701746"],"award-info":[{"award-number":["81701746"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s10620-020-06398-w","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T10:03:03Z","timestamp":1591783383000},"page":"1658-1668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn\u2019s Disease"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1319-5199","authenticated-orcid":false,"given":"Mingming","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xitao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"6398_CR1","doi-asserted-by":"crossref","unstructured":"Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46\u201354 e42; quiz e30.","DOI":"10.1053\/j.gastro.2011.10.001"},{"key":"6398_CR2","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/ecco-jcc\/jjz081","volume":"13","author":"SH Park","year":"2019","unstructured":"Park SH, Kim YJ, Rhee KH, et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986\u20132015. J Crohns Colitis. 2019;13:1410\u20131417.","journal-title":"J Crohns Colitis"},{"key":"6398_CR3","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10620-019-05819-9","volume":"65","author":"EM Song","year":"2020","unstructured":"Song EM, Lee HS, Kim YJ, et al. Incidence and outcomes of perianal disease in an asian population with Crohn\u2019s disease: a Nationwide Population-Based Study. Dig Dis Sci. 2020;65:1189\u20131196.","journal-title":"Dig Dis Sci"},{"key":"6398_CR4","first-page":"1839","volume":"19","author":"J Zhao","year":"2013","unstructured":"Zhao J, Ng SC, Lei Y, et al. First prospective, population-based inflammatory bowel disease incidence study in mainland of China: the emergence of \u201cwestern\u201d disease. Inflamm Bowel Dis. 2013;19:1839\u20131845.","journal-title":"Inflamm Bowel Dis"},{"key":"6398_CR5","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jgh.12164","volume":"28","author":"Z Zeng","year":"2013","unstructured":"Zeng Z, Zhu Z, Yang Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol. 2013;28:1148\u20131153.","journal-title":"J Gastroenterol Hepatol"},{"key":"6398_CR6","first-page":"1392","volume":"12","author":"WY Mak","year":"2018","unstructured":"Mak WY, Mak OS, Lee CK, et al. Significant medical and surgical morbidity in perianal Crohn\u2019s disease: results from a territory-wide study. J Crohns Colitis. 2018;12:1392\u20131398.","journal-title":"J Crohns Colitis"},{"key":"6398_CR7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","volume":"130","author":"L Beaugerie","year":"2006","unstructured":"Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn\u2019s disease. Gastroenterology. 2006;130:650\u2013656.","journal-title":"Gastroenterology"},{"key":"6398_CR8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/ibd\/izy329","volume":"25","author":"SH Park","year":"2019","unstructured":"Park SH, Aniwan S, Scott Harmsen W, et al. Update on the natural course of fistulizing perianal Crohn\u2019s disease in a population-based cohort. Inflamm Bowel Dis. 2019;25:1054\u20131060.","journal-title":"Inflamm Bowel Dis"},{"key":"6398_CR9","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00384-014-1935-6","volume":"29","author":"G Maconi","year":"2014","unstructured":"Maconi G, Gridavilla D, Vigano C, et al. Perianal disease is associated with psychiatric co-morbidity in Crohn\u2019s disease in remission. Int J Colorectal Dis. 2014;29:1285\u20131290.","journal-title":"Int J Colorectal Dis"},{"key":"6398_CR10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2036.2010.04486.x","volume":"33","author":"PJ Tozer","year":"2011","unstructured":"Tozer PJ, Burling D, Gupta A, et al. Review article: medical, surgical and radiological management of perianal Crohn\u2019s fistulas. Aliment Pharmacol Ther. 2011;33:5\u201322.","journal-title":"Aliment Pharmacol Ther"},{"key":"6398_CR11","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/gutjnl-2017-314918","volume":"67","author":"PG Kotze","year":"2018","unstructured":"Kotze PG, Shen B, Lightner AY, et al. Modern management of perianal fistulas in Crohn\u2019s disease: future directions. Gut. 2018;67:1181\u20131194.","journal-title":"Gut"},{"key":"6398_CR12","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med. 2004;350:876\u2013885.","journal-title":"N Engl J Med"},{"key":"6398_CR13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132:52\u201365.","journal-title":"Gastroenterology"},{"key":"6398_CR14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","volume":"14","author":"VBC Biemans","year":"2020","unstructured":"Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, et al. Ustekinumab for Crohn\u2019s disease: results of the ICC Registry, a nationwide prospective observational cohort study. J Crohns Colitis. 2020;14:33\u201345.","journal-title":"J Crohns Colitis"},{"key":"6398_CR15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369:711\u2013721.","journal-title":"N Engl J Med"},{"key":"6398_CR16","doi-asserted-by":"crossref","unstructured":"Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn\u2019s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63\u201370 e65; quiz e31.","DOI":"10.1053\/j.gastro.2011.09.034"},{"key":"6398_CR17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1365-2036.2005.02670.x","volume":"22","author":"E Domenech","year":"2005","unstructured":"Domenech E, Hinojosa J, Nos P, et al. Clinical evolution of luminal and perianal Crohn\u2019s disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther. 2005;22:1107\u20131113.","journal-title":"Aliment Pharmacol Ther"},{"key":"6398_CR18","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/gutjnl-2013-306709","volume":"63","author":"KB Gecse","year":"2014","unstructured":"Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn\u2019s disease. Gut. 2014;63:1381\u20131392.","journal-title":"Gut"},{"key":"6398_CR19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/ecco-jcc\/jjw039","volume":"10","author":"KB Gecse","year":"2016","unstructured":"Gecse KB, Sebastian S, Hertogh G, et al. Results of the fifth scientific workshop of the ECCO [II]: clinical aspects of perianal fistulising Crohn\u2019s disease-the unmet needs. J Crohns Colitis. 2016;10:758\u2013765.","journal-title":"J Crohns Colitis"},{"key":"6398_CR20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","volume":"11","author":"P Gionchetti","year":"2017","unstructured":"Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s Disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2017;11:135\u2013149.","journal-title":"J Crohns Colitis"},{"key":"6398_CR21","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/ibd.21940","volume":"18","author":"P Tozer","year":"2012","unstructured":"Tozer P, Ng SC, Siddiqui MR, et al. Long-term MRI-guided combined anti-TNF-alpha and thiopurine therapy for Crohn\u2019s perianal fistulas. Inflamm Bowel Dis. 2012;18:1825\u20131834.","journal-title":"Inflamm Bowel Dis"},{"key":"6398_CR22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.dld.2018.12.010","volume":"51","author":"M Chambaz","year":"2019","unstructured":"Chambaz M, Verdalle-Cazes M, Desprez C, et al. Deep remission on magnetic resonance imaging impacts outcomes of perianal fistulizing Crohn\u2019s disease. Dig Liver Dis. 2019;51:358\u2013363.","journal-title":"Dig Liver Dis"},{"key":"6398_CR23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/gastro\/goy036","volume":"7","author":"X Yan","year":"2019","unstructured":"Yan X, Zhu M, Feng Q, et al. Evaluating the effectiveness of infliximab on perianal fistulizing Crohn\u2019s disease by magnetic resonance imaging. Gastroenterol Rep (Oxf). 2019;7:50\u201356.","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"6398_CR24","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","volume":"19","author":"MS Silverberg","year":"2005","unstructured":"Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol.. 2005;19:5A\u201336A.","journal-title":"Can J Gastroenterol."},{"key":"6398_CR25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.gastro.2003.08.024","volume":"125","author":"American Gastroenterological Association Clinical Practice Committee","year":"2003","unstructured":"Committee American Gastroenterological Association Clinical Practice. American Gastroenterological Association medical position statement: perianal Crohn\u2019s disease. Gastroenterology. 2003;125:1503\u20131507.","journal-title":"Gastroenterology"},{"key":"6398_CR26","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med. 1999;340:1398\u20131405.","journal-title":"N Engl J Med"},{"key":"6398_CR27","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1038\/ajg.2009.509","volume":"104","author":"SC Ng","year":"2009","unstructured":"Ng SC, Plamondon S, Gupta A, et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn\u2019s perineal fistulas. Am J Gastroenterol. 2009;104:2973\u20132986.","journal-title":"Am J Gastroenterol"},{"key":"6398_CR28","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1572-0241.2003.07241.x","volume":"98","author":"Gert Van Assche","year":"2003","unstructured":"Van Assche Gert, Vanbeckevoort Dirk, Bielen Didier, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn\u2019s disease. Am J Gastroenterol. 2003;98:332\u2013339.","journal-title":"Am J Gastroenterol"},{"key":"6398_CR29","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2036.2009.04088.x","volume":"30","author":"SC Ng","year":"2009","unstructured":"Ng SC, Plamondon S, Gupta A, et al. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn\u2019s fistulas. Aliment Pharmacol Ther. 2009;30:757\u2013766.","journal-title":"Aliment Pharmacol Ther"},{"key":"6398_CR30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12876-019-1057-2","volume":"19","author":"Y Li","year":"2019","unstructured":"Li Y, Chen B, Gao X, et al. Current diagnosis and management of Crohn\u2019s disease in China: results from a multicenter prospective disease registry. BMC Gastroenterol. 2019;19:145.","journal-title":"BMC Gastroenterol"},{"issue":"975\u2013981","key":"6398_CR31","first-page":"e971","volume":"11","author":"G Bouguen","year":"2013","unstructured":"Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulizing Crohn\u2019s disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11(975\u2013981):e971\u2013e974.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6398_CR32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000458144","volume":"1","author":"J Zeitz","year":"2017","unstructured":"Zeitz J, Fournier N, Labenz C, et al. Risk factors for the development of fistulae and stenoses in Crohn disease patients in the swiss inflammatory bowel disease cohort. Inflamm Intest Dis. 2017;1:172\u2013181.","journal-title":"Inflamm Intest Dis"},{"key":"6398_CR33","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. The Lancet. 2002;359:1541\u20131549.","journal-title":"The Lancet"},{"key":"6398_CR34","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1007\/s10620-008-0545-y","volume":"54","author":"D Tougeron","year":"2009","unstructured":"Tougeron D, Savoye G, Savoye-Collet C, et al. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn\u2019s disease. Dig Dis Sci. 2009;54:1746\u20131752.","journal-title":"Dig Dis Sci"},{"key":"6398_CR35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MCG.0000000000000169","volume":"49","author":"C Casta\u00f1o-Milla","year":"2015","unstructured":"Casta\u00f1o-Milla C, Chaparro M, Saro C, et al. Effectiveness of adalimumab in perianal fistulas in crohn\u2019s disease patients naive to anti-TNF therapy. J Clin Gastroenterol. 2015;49:34\u201340.","journal-title":"J Clin Gastroenterol"},{"key":"6398_CR36","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/ecco-jcc\/jjz065","volume":"13","author":"A Schoepfer","year":"2019","unstructured":"Schoepfer A, Santos J, Fournier N, et al. Systematic analysis of the impact of diagnostic delay on bowel damage in paediatric versus adult onset Crohn\u2019s disease. J Crohns Colitis. 2019;13:1334\u20131342.","journal-title":"J Crohns Colitis"},{"key":"6398_CR37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2036.2003.01672.x","volume":"18","author":"P Lionetti","year":"2003","unstructured":"Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn\u2019s disease. Aliment Pharmacol Ther. 2003;18:425\u2013431.","journal-title":"Aliment Pharmacol Ther"},{"key":"6398_CR38","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ng.717","volume":"42","author":"A Franke","year":"2010","unstructured":"Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn\u2019s disease susceptibility loci. Nat Genet. 2010;42:1118\u20131125.","journal-title":"Nat Genet"},{"key":"6398_CR39","doi-asserted-by":"crossref","first-page":"318207","DOI":"10.1155\/2015\/318207","volume":"2015","author":"LM Medrano","year":"2015","unstructured":"Medrano LM, Taxonera C, Gonzalez-Artacho C, et al. Response to infliximab in Crohn\u2019s disease: genetic analysis supporting expression profile. Mediators Inflamm. 2015;2015:318207.","journal-title":"Mediators Inflamm"},{"key":"6398_CR40","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1002\/ibd.21301","volume":"16","author":"I Arijs","year":"2010","unstructured":"Arijs I, Quintens R, Van Lommel L, et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn\u2019s disease. Inflamm Bowel Dis. 2010;16:2090\u20132098.","journal-title":"Inflamm Bowel Dis"},{"key":"6398_CR41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","volume":"8","author":"J Cosnes","year":"2002","unstructured":"Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn\u2019s disease. Inflamm Bowel Dis. 2002;8:244\u2013250.","journal-title":"Inflamm Bowel Dis"},{"key":"6398_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz198","author":"DJ Lukin","year":"2019","unstructured":"Lukin DJ. predictors of perianal fistula relapse in Crohn\u2019s disease. Inflamm Bowel Dis. 2019;. https:\/\/doi.org\/10.1093\/ibd\/izz198.","journal-title":"Inflamm Bowel Dis"},{"key":"6398_CR43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s10620-017-4846-x","volume":"63","author":"A Osamura","year":"2018","unstructured":"Osamura A, Suzuki Y. Fourteen-year anti-TNF therapy in Crohn\u2019s disease patients: clinical characteristics and predictive factors. Dig Dis Sci. 2018;63:204\u2013208.","journal-title":"Dig Dis Sci"},{"key":"6398_CR44","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/apt.12906","volume":"40","author":"NA Yassin","year":"2014","unstructured":"Yassin NA, Askari A, Warusavitarne J, et al. Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn\u2019s disease. Aliment Pharmacol Ther. 2014;40:741\u2013749.","journal-title":"Aliment Pharmacol Ther"},{"key":"6398_CR45","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","volume":"41","author":"JF Colombel","year":"2015","unstructured":"Colombel JF, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn\u2019s disease\u2014a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015;41:734\u2013746.","journal-title":"Aliment Pharmacol Ther"},{"key":"6398_CR46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomollon","year":"2017","unstructured":"Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3\u201325.","journal-title":"J Crohns Colitis"},{"key":"6398_CR47","doi-asserted-by":"crossref","unstructured":"Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn\u2019s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2015;13:2233\u20132240 e2231\u20132232; quiz e2177\u20132238.","DOI":"10.1016\/j.cgh.2015.06.034"},{"key":"6398_CR48","doi-asserted-by":"crossref","first-page":"e11814","DOI":"10.1097\/MD.0000000000011814","volume":"97","author":"X Qian","year":"2018","unstructured":"Qian X, Wang T, Shen J, Ran Z. Low dose of azathioprine is effective to induce and maintain remission in active Crohn disease: a prospective observational study. Medicine (Baltimore). 2018;97:e11814.","journal-title":"Medicine (Baltimore)"},{"key":"6398_CR49","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/ibd\/izz061","volume":"25","author":"T Feng","year":"2019","unstructured":"Feng T, Chen B, Ungar B, et al. Association of infliximab levels with mucosal healing is time-dependent in Crohn\u2019s disease: higher drug exposure is required postinduction than during maintenance treatment. Inflamm Bowel Dis. 2019;25:1813\u20131821.","journal-title":"Inflamm Bowel Dis"},{"key":"6398_CR50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ibd\/izy217","volume":"25","author":"W El-Matary","year":"2019","unstructured":"El-Matary W, Walters TD, Huynh HQ, et al. Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal Crohn\u2019s disease in children. Inflamm Bowel Dis. 2019;25:150\u2013155.","journal-title":"Inflamm Bowel Dis"},{"key":"6398_CR51","first-page":"549","volume":"11","author":"Y Davidov","year":"2017","unstructured":"Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of induction infliximab levels with clinical response in perianal Crohn\u2019s disease. J Crohns Colitis. 2017;11:549\u2013555.","journal-title":"J Crohns Colitis"},{"key":"6398_CR52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MEG.0000000000001561","volume":"32","author":"N Plevris","year":"2020","unstructured":"Plevris N, Jenkinson PW, Arnott ID, et al. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn\u2019s disease. Eur J Gastroenterol Hepatol. 2020;32:32\u201337.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06398-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06398-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06398-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T23:12:08Z","timestamp":1623280328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06398-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["6398"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06398-w","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"12 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}